News Releases

Date Title
08/30/18
Summary ToggleSunesis Pharmaceuticals to Present at the Wells Fargo Securities 2018 Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , Aug. 30, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn , Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the Wells Fargo Securities 2018

08/07/18
Summary ToggleSunesis Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Highlights

Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the quarter ended June 30, 2018 . Loss from operations for the three and six months ended

07/31/18
Summary ToggleSunesis Pharmaceuticals to Host Conference Call on August 7th to Discuss Second Quarter 2018 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif. , July 31, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Tuesday, August 7 th , 2018 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the second quarter ended

07/09/18
Summary ToggleSunesis Pharmaceuticals Strengthens Senior Management Team

SOUTH SAN FRANCISCO, Calif. , July 09, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced three key new management appointments as part of the Company’s expansion of its development team. Deepali Suri , M.Sc., a former Executive Director at Pharmacyclics (an AbbVie

06/25/18
Summary ToggleSunesis Pharmaceuticals Enters into $15.5 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC

SOUTH SAN FRANCISCO, Calif. , June 25, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it has entered into a Common Shares Purchase Agreement (the “Agreement”) of up to $15.5 million with Aspire Capital Fund, LLC (“Aspire Capital”).

06/18/18
Summary ToggleSunesis Pharmaceuticals Announces Presentations at the EHA Annual Meeting

Université Claude Bernard de Lyon Study Provides Preclinical Validation of Vecabrutinib Activity Against Ibrutinib-Resistant BTK C481S Mutated Lymphomas ERIC Study Shows Half of Ibrutinib-Relapse CLL Patients Carry BTK C481S Mutations SOUTH SAN FRANCISCO, Calif.

05/08/18
Summary ToggleSunesis Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Highlights

Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , May 08, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the first quarter ended March 31, 2018 . Loss from operations for the three months ended

05/01/18
Summary ToggleSunesis Pharmaceuticals to Host Conference Call on May 8th to Discuss First Quarter 2018 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif. , May 01, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Tuesday, May 8 th , 2018 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended March

03/14/18
Summary ToggleSunesis Pharmaceuticals to Present at Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. , March 14, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will present at two upcoming investor conferences. Willie Quinn , Chief Financial Officer and Senior Vice President, Finance and Corporate Development of
03/13/18
Summary ToggleSunesis Pharmaceuticals Announces Cancellation of Presentation and Webcast at Cowen & Company 38th Annual Health Care Conference Cancellation due to Travel Changes Caused by Inclement Weather Management to Proceed with Scheduled Investor Meetings via Conference Calls SOUTH SAN FRANCISCO, Calif. , March 13, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the cancellation of the company’s
03/08/18
Summary ToggleSunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , March 08, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the fourth quarter and year ended December 31, 2017 .
03/06/18
Summary ToggleSunesis Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference SOUTH SAN FRANCISCO, Calif. , March 06, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Willie Quinn , Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the Cowen and Company 38 th Annual Health
03/01/18
Summary ToggleSunesis Pharmaceuticals to Host Conference Call on March 8th to Discuss Fourth Quarter and Full-Year 2017 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , March 01, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, March 8th, 2018 at 1:30 p.m. Pacific Time to discuss corporate updates and financial results for the fourth quarter and year
02/07/18
Summary ToggleSunesis Pharmaceuticals Appoints Industry Veteran H. Ward Wolff to the Board of Directors SOUTH SAN FRANCISCO, Calif. , Feb. 07, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that H. Ward Wolff has been appointed to the Sunesis Board of Directors. Mr. Wolff brings over 40 years of finance and executive leadership experience to the Board, with 20